Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
309.01
-1.70 (-0.55%)
At close: Mar 9, 2026, 4:00 PM EDT
315.19
+6.18 (2.00%)
After-hours: Mar 9, 2026, 5:55 PM EDT
PRAX Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
168
Market Cap
8.61B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
PRAX News
- 3 days ago - Praxis Precision Medicines, Inc. (PRAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 5 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 17 days ago - Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results - Benzinga
- 18 days ago - Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders - Business Wire
- 6 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch